chr22-38657377-A-G
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_015373.4(CBY1):c.-39+627A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.294 in 152,048 control chromosomes in the GnomAD database, including 6,643 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.29 ( 6643 hom., cov: 32)
Consequence
CBY1
NM_015373.4 intron
NM_015373.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.172
Publications
6 publications found
Genes affected
CBY1 (HGNC:1307): (chibby 1, beta catenin antagonist) Beta-catenin is a transcriptional activator and oncoprotein involved in the development of several cancers. The protein encoded by this gene interacts directly with the C-terminal region of beta-catenin, inhibiting oncogenic beta-catenin-mediated transcriptional activation by competing with transcription factors for binding to beta-catenin. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
CBY1 Gene-Disease associations (from GenCC):
- ciliopathyInheritance: AR Classification: MODERATE Submitted by: Ambry Genetics
- Joubert syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.83).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.344 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| CBY1 | NM_015373.4 | c.-39+627A>G | intron_variant | Intron 1 of 4 | ENST00000216029.8 | NP_056188.1 | ||
| CBY1 | NM_001002880.4 | c.-179+627A>G | intron_variant | Intron 1 of 5 | NP_001002880.3 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.294 AC: 44616AN: 151926Hom.: 6633 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
44616
AN:
151926
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.294 AC: 44661AN: 152048Hom.: 6643 Cov.: 32 AF XY: 0.294 AC XY: 21832AN XY: 74322 show subpopulations
GnomAD4 genome
AF:
AC:
44661
AN:
152048
Hom.:
Cov.:
32
AF XY:
AC XY:
21832
AN XY:
74322
show subpopulations
African (AFR)
AF:
AC:
11939
AN:
41456
American (AMR)
AF:
AC:
3606
AN:
15264
Ashkenazi Jewish (ASJ)
AF:
AC:
994
AN:
3466
East Asian (EAS)
AF:
AC:
1847
AN:
5170
South Asian (SAS)
AF:
AC:
1361
AN:
4828
European-Finnish (FIN)
AF:
AC:
3534
AN:
10580
Middle Eastern (MID)
AF:
AC:
94
AN:
292
European-Non Finnish (NFE)
AF:
AC:
20316
AN:
67974
Other (OTH)
AF:
AC:
604
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
1618
3237
4855
6474
8092
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
466
932
1398
1864
2330
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1121
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.